Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) announced its quarterly earnings data on Thursday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock traded up $0.39 during trading on Friday, reaching $13.79. The company had a trading volume of 82,088 shares, compared to its average volume of 465,206. The company has a 50-day moving average of $13.01. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BCAX shares. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.